JW Jungwoo Pharmaceutical "Livalo Recognized for Diabetes Safety in 31 Countries"

[Asia Economy Reporter Cho Hyun-ui] The number of countries recognizing the diabetes safety of JW Pharmaceutical's hyperlipidemia treatment 'Livalo' (active ingredient: Pitavastatin) has increased from 21 to 31.

On the 22nd, JW Pharmaceutical announced, "A total of 10 countries including Singapore, Malaysia, Lebanon, Saudi Arabia, Bahrain, Jordan, Kuwait, Oman, Qatar, and the United Arab Emirates have recognized Livalo's safety regarding diabetes."

Livalo was first approved by the UK's regulatory authority in March 2016, and by August last year, it had been recognized by regulatory agencies in a total of 21 countries including Portugal, Greece, Germany, and France. With the addition of these 10 countries, Livalo is now the only statin whose drug label (SmPC) can include the phrase 'No signs of increased diabetes risk.'

A JW Pharmaceutical official explained, "The safety of Livalo has been recognized in 31 countries based on research showing that Pitavastatin reduces the risk of diabetes by approximately 18% compared to placebo, as well as a meta-analysis of 15 studies conducted with Pitavastatin."

They added, "Various recently published academic data have once again proven that Pitavastatin is the only statin with a low risk of causing diabetes. We expect this trend to spread to more countries in the future."

This content was produced with the assistance of AI translation services.